To build a world-class biomedical industrial cluster

■ We welcome all kinds of innovative biomedicine enterprises to combine their own advantages with Shanghai's industrial, market and resource advantages, increase investment and improve the layout of production and research and development in Shanghai. We will continue to foster a law-based, market-oriented and international business environment, strengthen policy provision, deepen service synergy, and support enterprises to achieve faster and better development in Shanghai

■ At present, the R&D innovation model in the field of biomedicine is undergoing profound changes, and the period from basic research to industrialization is greatly shortened, which is both a challenge and an opportunity. We need to deepen understanding, speed up the layout of frontier areas and new racetracks, and firmly grasp the initiative of development

■ We should build benchmarking professional incubators, make good use of various public platforms, accelerate the cultivation of a number of high-growth enterprises, and form a number of industry leading enterprises

■ We should set the highest international standards and the best level, strive to create the industrial ecology, attract more outstanding enterprises and top talents to join the development of biomedicine industry in Shanghai, and jointly build a world-class biomedicine industry cluster

According to the arrangement of the theme education work of the Municipal Committee and the deployment of Daxing investigation and research, yesterday morning, Chen Jining, the secretary of the Municipal Committee, centered on the theme of the development of the biomedicine industry, went deep into the domestic and foreign biomedicine and medical device enterprises to carry out a special investigation, carefully listening to the opinions and suggestions of the enterprises.  We will continue to enhance the core competitiveness of our industries to provide strong support for building a modern industrial system and promoting high-quality economic development.

Growing from Zhangjiang Science City, Minimally Invasive Group is committed to R&D and production of independent innovative high-end medical devices, and has formed a global R&D, production, marketing and service network. Chen Jining came to the headquarters of the group to learn about the global layout and development vision of the company. In the remote guidance center and the Medical Engineering Experience Center, he inspected the remote application demonstration of surgical robots and the newly developed high-end medical instruments, and made specific understanding of the Group's building of industrial incubators and helping the development of start-ups. Listen to enterprise leaders on strengthening the ability of independent innovation, in-depth medical device market segmentation ideas and suggestions. As a leading R&D driven biopharmaceutical company in the world, Boehringer Ingelheim has been in the Chinese market for nearly 30 years, and now has achieved an industry-wide layout and simultaneous global R&D activities, covering human pharmaceuticals, animal health and biopharmaceutical contract production. Municipal leaders came to Boehringer Ingelheim Bio-Pharmaceutical (China) Co., Ltd. to inspect the production lines and laboratories in the production building, listen to the company's R&D and production progress in Shanghai, domestic and global, learn about the new drug commissioning service for innovative enterprises, and ask what problems need to be solved in the next development. Officials of the company said that thanks to Shanghai's sound business environment and service docking mechanism, it has received strong support in intellectual property protection and new drug R&D and marketing. They look forward to further exploration in global synchronous research and development, policy first trial and other aspects. Chen Jining said that biopharmaceutical is one of the three leading industries vigorously developed in Shanghai. We welcome all kinds of innovative biopharmaceutical enterprises to combine their own advantages with Shanghai's industrial advantages, market advantages and resource advantages more closely, increase investment in Shanghai, improve the layout of production and research and development. We will continue to foster a law-based, market-oriented and international business environment, strengthen policy provision, deepen service synergy, and support enterprises to achieve faster and better development in Shanghai. Relevant districts and departments should step forward, take the initiative, keep in touch with each other, timely help enterprises to solve practical difficulties, and help enterprises to innovate and develop without distractions.

Chen Jining pointed out that combining theme education and Daxing investigation and research, it is necessary to further identify the problems restricting the high-quality development of the biomedical industry, strengthen analysis, research and judgment, focus on the causes and crux, come up with solutions, and effectively form a group of targeted and breakthrough guidance and support policies. At present, the R&D innovation mode in the field of biomedicine is undergoing profound changes, and the period from basic research to industrialization is greatly shortened, which is both a challenge and an opportunity. We need to deepen understanding, speed up the layout of frontier areas and new racetracks, and firmly grasp the initiative of development. It is necessary to build benchmarking professional incubators, make good use of various public platforms, accelerate the cultivation of a number of high-growth enterprises, form a number of industry leading enterprises, and better support the high-quality development of the biomedical industry. It is necessary to set the highest international standards and the best level, make every effort to create the industrial ecology, focus on agglomeration, leading and driving, further optimize the spatial layout, gather resources and elements, and improve service supporting facilities, attract more outstanding enterprises and top talents to join the development of biomedicine industry in Shanghai, and jointly build a world-class biomedicine industry cluster.

City leaders Zhang Wei, Li Zheng, the central Fifth Steering Group related responsible comrades to participate in the research.

Source: Jiefang Daily